Please assess the completion status of the following clinical trial:

Trial Title: A 28 Day Study of ONO-9054 Ophthalmic Solution in Subjects With Ocular Hypertension (OHT) or Open-angle Glaucoma (OAG)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female aged 18-85 (inclusive) with confirmed diagnosis of OHT or OAG~* Confirmed diagnosis of bilateral OHT or mild to moderate chronic OAG~* Able to undergo washout of all ocular drugs~* An IOP ≥ 24 mmHg at 8:00 AM and ≥ 21 mmHg at 10:00 AM in at least 1 eye; but \< 36 mmHg in both eyes at both Day -5 and Day 1~* Central corneal thickness 500-620 µm at screening and Day -5 in both eyes~* Best corrected visual acuity (BCVA) of +0.7 Log Mar or better~Exclusion Criteria:~* Any history of severe ocular trauma in either eye at any time~* History of angle closure or ocular laser surgery within the past 3 months or any refractive surgery procedure within the past 6 months of Screening Visit in the study eye(s)~* Cataracts that prevent observation or photography of the fundus in either eye

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Experimental Arm 1 (Type: EXPERIMENTAL): ONO-9054 eye drop solution, 30 µg/mL (0.003%), once daily in both eyes, for 28 days.
- Active Comparator Arm 2 (Type: ACTIVE_COMPARATOR): Latanoprost eye drop solution, 0.005%, once daily in both eyes for 28 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).